You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm is positioning the technology, called Morffi, for use in lateral flow immunoassays, particularly in infectious disease diagnostics, such as influenza tests.
Researchers at the University of Washington have developed a diagnostic platform that leverages the lateral flow immunoassay concept using quantum dots, a mobile phone, and an ultraviolet light-emitting diode.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The platform, which was first developed to transmit flu data to the CDC, is expanding to multiple use cases and multiple users.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The medium has been cleared for transporting samples potentially containing flu A and tuberculosis.
Through its large network of ambulatory labs, the university's pathology and lab medicine department is evaluating a BioFire rapid diagnostic test for the flu.